Introduction There is an urgent need to check the efficacy of SARS-CoV-2 vaccination among hemodialyzed (HD) patients known to have extensive disturbances of acquired immunity and a catastrophic risk of death from COVID-19. Objectives In a cross-sectional study we aimed to assess the humoral response following vaccination with the BNT162b2 (BioNTech / Pfizer Comirnaty) vaccine. Patients and methods We analyzed the titer magnitude of the IgG antibodies directed against spike (S)- SARS-CoV-2 antigen 14-21 days after the second dose of the BNT162b2 vaccine in a group of HD patients who have not been confirmed with SARS-CoV-2 infection yet, compared to patients with a history of COVID-19. 126 HD patients were stratified based on evidence of a previous infection with SARS-COV-2 confirmed with viral RNA detection or nucleocapsid-specific IgG antibodies detection. Results s-antigen immune response with a median (IQR) antibody titer of 366 (193-691) UA/ml was seen in 87 of 91 infection naïve (IN)-HD patients (95.6%). In 68 of 91 IN-HD patients (74.7%) a strong humoral response was observed with titer anti-S antibodies above 200 UA/ml. Older subjects were less likely to develop an S-antibodies response (P <0.001). The median S-antigen antibody titer in 35 previously infected (PI)-HD patients was over 12-fold higher than in IN-HD patients; 4620 (1240-7820) UA/ml (P <0.001). There were no significant differences in S-antibody titer between symptomatic and asymptomatic PI-HD patients. Conclusions Our study demonstrated that the majority of HD patients achieved a high immunization rate after vaccination with BNT162b2. Whether this translates into protecting this population from COVID-19 requires further research.

中文翻译：

---

由于 COVID-19，对 SARS-CoV-2 疫苗接种的体液反应有望改善血液透析患者的灾难性预后。COViNEPH 项目。

简介 迫切需要检查 SARS-CoV-2 疫苗接种在已知具有广泛获得性免疫紊乱和因 COVID-19 死亡的灾难性风险的血液透析 (HD) 患者中的功效。目的 在一项横断面研究中，我们旨在评估接种 BNT162b2（BioNTech / Pfizer Comirnaty）疫苗后的体液反应。患者和方法 我们分析了一组未确诊 SARS 的 HD 患者在第二剂 BNT162b2 疫苗接种后 14-21 天针对尖峰 (S)-SARS-CoV-2 抗原的 IgG 抗体的滴度大小- 与有 COVID-19 病史的患者相比，尚未感染 CoV-2。根据病毒 RNA 检测或核衣壳特异性 IgG 抗体检测证实的先前感染 SARS-COV-2 的证据对 126 名 HD 患者进行分层。结果 91 名未感染 (IN)-HD 患者中的 87 名 (95.6%) 观察到 s 抗原免疫反应，中位 (IQR) 抗体滴度为 366 (193-691) UA/ml。在 91 名 IN-HD 患者中的 68 名 (74.7%) 中观察到强烈的体液反应，抗 S 抗体滴度高于 200 UA/ml。年龄较大的受试者不太可能产生 S 抗体反应 (P <0.001)。35 名先前感染 (PI)-HD 患者的 S 抗原抗体滴度中位数比 IN-HD 患者高 12 倍以上；4620 (1240-7820) UA/ml (P <0.001)。有症状和无症状 PI-HD 患者的 S 抗体滴度没有显着差异。结论 我们的研究表明，大多数 HD 患者在接种 BNT162b2 后实现了高免疫率。这是否转化为保护这一人群免受 COVID-19 的侵害需要进一步研究。